C. Ola Landgren, MD (IMAGE)

University of Miami Miller School of Medicine

C. Ola Landgren, MD

Caption

“This study shows that daratumumab added to KRd is a new standard of care for those patients who had previously been candidates for just KRd,” said C. Ola Landgren, M.D., Ph.D., director of the Myeloma Institute at Sylvester Comprehensive Cancer Center.

Credit

Photo by Sylvester Comprehensive Cancer Center

Usage Restrictions

Please include attribution/photo credit

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.